Cyclo Financial Statements From 2010 to 2025

CYTHW Stock  USD 0.30  0.01  3.45%   
Cyclo Therapeutics financial statements provide useful quarterly and yearly information to potential Cyclo Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Cyclo Therapeutics financial statements helps investors assess Cyclo Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Cyclo Therapeutics' valuation are summarized below:
Gross Profit
M
Market Capitalization
62.8 M
Revenue
1.1 M
Quarterly Revenue Growth
0.051
Revenue Per Share
0.046
There are over one hundred nineteen available fundamental signals for Cyclo Therapeutics, which can be analyzed over time and compared to other ratios. All traders should should validate Cyclo Therapeutics' prevailing fundamental trends against the trends from 2010 to 2025 to make sure the company is sustainable. Market Cap is likely to climb to about 24.5 M in 2025. Enterprise Value is likely to climb to about 16.8 M in 2025

Cyclo Therapeutics Total Revenue

1 Million

Check Cyclo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cyclo Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 21.1 K, Interest Expense of 181.7 K or Total Revenue of 1 M, as well as many indicators such as Price To Sales Ratio of 22.79, Dividend Yield of 0.0 or PTB Ratio of 7.66. Cyclo financial statements analysis is a perfect complement when working with Cyclo Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Cyclo Therapeutics Correlation against competitors.
For more information on how to buy Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.

Cyclo Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets16 M15.2 MM
Slightly volatile
Short and Long Term Debt Total1.2 M1.2 M595.2 K
Pretty Stable
Total Current Liabilities10.2 M9.7 M3.1 M
Slightly volatile
Total Stockholder Equity5.7 M5.5 M3.8 M
Slightly volatile
Property Plant And Equipment Net708.5 K1.1 M748.8 K
Slightly volatile
Accounts Payable5.9 M5.6 M2.1 M
Slightly volatile
Cash11.2 M10.6 M4.6 M
Slightly volatile
Non Current Assets Total696.5 K836.4 K959.5 K
Slightly volatile
Cash And Short Term Investments11.2 M10.6 M4.6 M
Slightly volatile
Net Receivables106.4 K140.7 K121.8 K
Slightly volatile
Common Stock Shares Outstanding19.7 M18.8 M4.8 M
Slightly volatile
Liabilities And Stockholders Equity16 M15.2 MM
Slightly volatile
Inventory251.9 K292.5 K311 K
Very volatile
Other Current Assets3.3 M3.1 M1.1 M
Slightly volatile
Other Stockholder Equity107 M101.9 M35.6 M
Slightly volatile
Total Liabilities10.3 M9.8 M3.2 M
Slightly volatile
Total Current Assets14.9 M14.2 MM
Slightly volatile
Short Term Debt1.1 MM529.5 K
Slightly volatile
Intangible Assets10.2 K8.6 K10.5 K
Slightly volatile
Common Stock3.6 K3.3 K4.4 K
Very volatile
Common Stock Total Equity9289763.9 K
Pretty Stable
Property Plant And Equipment Gross533.5 K945.1 K744 K
Slightly volatile
Other Current Liabilities2.7 M2.6 M1.8 M
Slightly volatile
Short Term Investments104.5 K90 K103.2 K
Slightly volatile
Capital Surpluse77.9 M74.2 M32.9 M
Slightly volatile
Property Plant Equipment51.7 K63.5 K43 K
Slightly volatile
Net Invested Capital5.5 M5.5 M3.4 M
Slightly volatile
Net Working Capital5.2 M4.4 M3.1 M
Slightly volatile
Capital Stock3.5 K2.6 K6.6 K
Slightly volatile
Long Term Debt25 K16.2 K36.6 K
Slightly volatile
Short and Long Term Debt136.3 K153.8 K121.6 K
Slightly volatile
Net Tangible Assets587.6 K661.1 K720.8 K
Slightly volatile

Cyclo Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization21.1 K22.2 K66.1 K
Slightly volatile
Total RevenueM1.2 M1.2 M
Pretty Stable
Other Operating Expenses25.5 M24.3 M9.2 M
Slightly volatile
Cost Of Revenue93.5 K98.5 K368 K
Pretty Stable
Total Operating Expenses22.1 M21 M8.4 M
Slightly volatile
Selling General Administrative6.8 M6.5 M3.4 M
Slightly volatile
Selling And Marketing Expenses6.7 K3.5 K8.6 K
Slightly volatile
Research Development17.1 M16.3 M5.3 M
Slightly volatile
Interest Income15.8 K22.8 K17.3 K
Pretty Stable
Reconciled Depreciation14.7 K22.2 K12.2 K
Slightly volatile
Non Recurring8.2 K9.2 K10.1 K
Slightly volatile
Non Operating Income Net Other136.8 K153.9 K167.8 K
Slightly volatile

Cyclo Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash FlowM1.8 M2.9 M
Slightly volatile
Depreciation16.5 K17.3 K56.6 K
Slightly volatile
Capital Expenditures2.1 K2.2 K105.3 K
Slightly volatile
End Period Cash Flow11.2 M10.6 M4.6 M
Slightly volatile
Stock Based Compensation889.8 K847.5 K306.4 K
Slightly volatile
Other Cashflows From Investing Activities45.5 K47.9 K440.9 K
Slightly volatile
Issuance Of Capital Stock11.3 M10.6 M7.3 M
Slightly volatile
Change To Netincome269.3 K303 K330.3 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio22.7921.7119.095
Slightly volatile
PTB Ratio7.664.9113.3558
Very volatile
Days Sales Outstanding31.0837.3535.555
Slightly volatile
Book Value Per Share0.320.342.9277
Slightly volatile
Average Payables2.8 M2.7 M1.6 M
Slightly volatile
Stock Based Compensation To Revenue0.650.620.2736
Slightly volatile
Capex To Depreciation0.140.12552.1538
Slightly volatile
PB Ratio7.664.9113.3558
Very volatile
Inventory Turnover0.420.450.6768
Slightly volatile
Days Of Inventory On Hand543849836
Slightly volatile
Payables Turnover0.02210.02330.663
Slightly volatile
Sales General And Administrative To Revenue4.974.732.7843
Slightly volatile
Average Inventory170.6 K229 K307.9 K
Pretty Stable
Research And Ddevelopement To Revenue12.4511.864.2593
Slightly volatile
Capex To Revenue0.00250.00260.1062
Slightly volatile
Cash Per Share0.480.511.9076
Very volatile
Days Payables Outstanding17 K16.2 KK
Slightly volatile
Intangibles To Total Assets0.00540.00570.0075
Slightly volatile
Current Ratio1.591.672.1938
Pretty Stable
Tangible Book Value Per Share0.320.342.8853
Slightly volatile
Receivables Turnover15.010.1215.3365
Slightly volatile
Graham Number3.13.2612.0536
Slightly volatile
Shareholders Equity Per Share0.320.342.9277
Slightly volatile
Debt To Equity0.240.250.3615
Slightly volatile
Capex Per Share2.0E-42.0E-40.3875
Slightly volatile
Average Receivables280.7 K267.3 K155.5 K
Slightly volatile
Revenue Per Share0.0720.07582.0573
Slightly volatile
Interest Debt Per Share0.06910.07281.1341
Slightly volatile
Debt To Assets0.08520.08970.1313
Slightly volatile
Operating Cycle574886871
Slightly volatile
Price Book Value Ratio7.664.9113.3558
Very volatile
Days Of Payables Outstanding17 K16.2 KK
Slightly volatile
Ebt Per Ebit1.181.151.0178
Pretty Stable
Company Equity Multiplier2.933.22.5972
Pretty Stable
Long Term Debt To Capitalization0.00130.00130.1168
Slightly volatile
Total Debt To Capitalization0.310.210.2023
Slightly volatile
Debt Equity Ratio0.240.250.3615
Slightly volatile
Quick Ratio3.111.641.9104
Slightly volatile
Net Income Per E B T1.511.141.0396
Pretty Stable
Cash Ratio1.490.981.5088
Slightly volatile
Days Of Inventory Outstanding543849836
Slightly volatile
Days Of Sales Outstanding31.0837.3535.555
Slightly volatile
Price To Book Ratio7.664.9113.3558
Very volatile
Fixed Asset Turnover0.991.0414.4518
Pretty Stable
Debt Ratio0.08520.08970.1313
Slightly volatile
Price Sales Ratio22.7921.7119.095
Slightly volatile
Asset Turnover0.08880.09340.3308
Slightly volatile
Gross Profit Margin0.680.820.844
Pretty Stable
Price Fair Value7.664.9113.3558
Very volatile

Cyclo Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap24.5 M23.4 M11.2 M
Slightly volatile

Cyclo Fundamental Market Drivers

Cash And Short Term Investments9.2 M

About Cyclo Therapeutics Financial Statements

Cyclo Therapeutics investors use historical fundamental indicators, such as Cyclo Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cyclo Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-3.3 M-3.1 M
Total Revenue1.2 MM
Cost Of Revenue98.5 K93.5 K
Stock Based Compensation To Revenue 0.62  0.65 
Sales General And Administrative To Revenue 4.73  4.97 
Research And Ddevelopement To Revenue 11.86  12.45 
Revenue Per Share 0.08  0.07 
Ebit Per Revenue(21.42)(20.35)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Cyclo Stock Analysis

When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.